article thumbnail

Beyond Medicalization: Psychedelic Therapy and the Promise of Community-Based Healing

Mad in America

House Bill 25-1063 , approved in April 2025, represents one such effort, revealing the intersection of commercial interests, intellectual property concerns, and the pharmaceutical model’s influence on psychedelic policy. This one-size-fits-all approach reflects the reductionist tendencies of conventional psychiatry.

article thumbnail

One Person’s Journey from Celebrity Medical Model Advocate to Skeptic: An Interview with Rose Cartwright

Mad in America

You write that you worry about how psychedelics are getting co-opted by pharmaceutical industries. Cartwright: I do an exercise in my book where I speculate that if psychedelic therapy been available to my mother when she was at her worst, would it have been helpful? Dhar: That was my favorite part, the gentleness.

article thumbnail

A Win for Science, with Profound Implications for Industry: FDA Rejects MDMA

Mad in America

Or perhaps the rejection of Lykos’ drug reveals something else: the powerful influence of the traditional pharmaceutical lobby at the cost of the upstart psychedelic industry. Moreover, Lykos is a small company bringing it to market, one that emerged out of a psychedelic research nonprofit (MAPS). We may never know.